Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
The mechanistic rationale is described in the phase 2 publications by Rosenstock et al
E., Kas, M
GSBR-1290: While still in development, GSBR-1290 is another oral GLP-1 antagonist used to manage chronic obesity and type 2 diabetes compared to Orforglipron
The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate MOTS from nearby GLP-1, peptide, hormone, or provider-comparison searches
Eli Lilly and Company reported that its investigational oral GLP-1 receptor agonist, orforglipron, achieved superior oral GLP-1 receptor agonist performance in type 2 diabetes management compared with oral semaglutide in a head-to-head phase 3 trial Furthermore, RPG Life Sciences is sharpening its strategy today with a strong focus on its GLP-1 entry plan and expanding API business, signaling a shift toward high-growth pharmaceutical segments
